Publikatsioonid
2018
Soodla P, Simmons R, Huik K, Pauskar M, Jõgeda EL, Rajasaar H, Kallaste E, Maimets M, Avi R, Murphy G, Porter K, Lutsar I; Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) Collaboration in EuroCoord HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay.
2017
Huik, Kristi; Soodla, Pilleriin; Pauskar, Merit; Rajasaar, Heli; Jõgeda, Ene-Ly; Eveli, Kallas; Avi, Radko; Lutsar, Irja The evaluation of two HIV-1 incidence assays in subjects infected with non-B subtype viruses. ECCMID 2017
Stirrup OT, Copas AJ, Phillips AN, Gill MJ, Geskus RB, Touloumi G, Young J, Bucher HC, Babiker AG; CASCADE Collaboration in EuroCoord Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion.
Ghosn J, Bayan T, Meixenberger K, Tran L, Frange P, d’Arminio Monforte A, Zangerle R, de Mendoza C, Krastinova E, Porter K, Meyer L, Chaix ML; CASCADE Collaboration in EuroCoord CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus
2016
Laisaar, Kaja-Triin; Raag, Mait; Lutsar, Irja; Uusküla, Anneli People living with HIV in Estonia: engagement in HIV care in 2013. Euro Surveill. 2016 Oct 27;21(43)
Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs. Medical microbiology and immunology, 205 (3), 231−239
Avi, Radko; Pauskar, Merit; Karki, Tõnis; Kallas, Eveli; Jõgeda, Ene-Ly; Margus, Tõnu; Huik, Kristi; Lutsar, Irja (2016). Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia. Journal of Medical Virology, 88 (3), 448−454, 10.1002/jmv.24361.
Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use. Viral immunology, 0−0.
Huik, Kristi; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Jõgeda, Ene-Ly; Karki, Tõnis; Rüütel, Kristi; Talu, Ave; Abel-Ollo, Katri; Uusküla, Anneli; Carrillo, Andrew; Ahuja, Sunil K; He, Weijing; Lutsar, Irja (2016). A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. PloS one, 11 (6), e0156850−e0156850, 10.1371/journal.pone.0156850.
Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi (2016). Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 43, 83−85, 10.1016/j.meegid.2016.05.022.
2015
Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2015). Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs. Medical microbiology and immunology, 1−9, 10.1007/s00430-015-0444-8.
Rhee, S.-Y.; Blanco, J.L.; Jordan, M.R.; Taylor, J.; Lemey, P.; Varghese, V.; Hamers, R.L.; Bertagnolio, S.; de Wit, T.F.R.; Aghokeng, A.F.; Albert, J.; Avi, R.; Avila-Rios, S.; Bessong, P.O.; Brooks, J.I.; Boucher, C.A.B.; Brumme, Z.L.; Busch, M.P.; Bussmann, H.; Chaix, M.-L.; Chin, B.S.; DâAquin, T.T.; De Gascun, C.F.; Derache, A.; Descamps, D.; Deshpande, A.K.; Djoko, C.F.; Eshleman, S.H.; Fleury, H.; Frange, P.; Fujisaki, S.; Harrigan, P.R.; Hattori, J.; Holguin, A.; Hunt, G.M.; Ichimura, H.; Kaleebu, P.; Katzenstein, D.; Kiertiburanakul, S.; Kim, J.H.; Kim, S.S.; Li, Y.; Lutsar, I.; Morris, L.; Ndembi, N.; NG, K.P.; Paranjape, R.S.; Peeters, M.; Poljak, M.; Price, M.A.; Ragonnet-Cronin, M.L.; Reyes-Terán, G.; Rolland, M.; Sirivichayakul, S.; Smith, D.M.; Soares, M.A.; Soriano, V.V.; Ssemwanga, D.; Stanojevic, M.; Stefani, M.A.; Sugiura, W.; Sungkanuparph, S.; Tanuri, A.; Tee, K.K.; Truong, H.-H.M.; van de Vijver, D.A.M.C.; Vidal, N.; Yang, C.; Yang, R.; Yebra, G.; Ioannidis, J.P.A.; Vandamme, A.-M.; Shafer, R.W. (2015). Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis (PLoS Medicine). PLOS Medicine, 12(4), 1001810
Kallas, E.; Huik, K.; Pauskar, M.; Jõgeda,E.-L.; Karki, T.; Des Jarlais, D.; Uusküla, A.; Avi, R.; Lutsar, I. (2015). Influence of interleukin 10 polymorphisms -592 and -1082 to the HIV, HBV and HCV serostatus among intravenous drug users. Infection, genetics and evolution, 30, 175 – 180.
2014
Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki,T; Kallas, E; Jõgeda, EL; Krispin, T; Lutsar, I (2014). Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1 CRF06_cpx-infected patients in Estonia in 2010. AidsResearch and Human Retroviruses, 30(3), 278 – 283.
Huik, K.; Avi, R.; Uibopuu, H.; Pauskar, M.; Margus, T.; Karki, T.; Krispin, T.; Kool, P.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Carrillo, AQ.; He, W.; Ahuja, SK.; Lutsar, I. (2014). Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population. Jaids-Journal of Acquired Immune Deficiency Syndromes, 66(3), 239 – 244.
2013
Huik, K; Avi, R; Pauskar, M; Kallas, E;Jõgeda, EL; Karki, T; Marsh, K; Des Jarlais, D; Uusküla, A; Lutsar, I (2013). Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. Infection,genetics and evolution, 20, 78 – 82.
Huik, K; Avi, R; Carrillo, A; Harper, N;Pauskar, M; Sadam, M; Karki, T; Krispin, T; He, W; Lutsar, I (2013). CCR5 Haplotypes Influence HCV Serostatus in Caucasian Intravenous Drug Users. PLoS ONE, 8(7), e70561
Lodi, S; del Amo, J; d’Arminio Monforte, A;Abgrall, S; Sabin, C; Morrison, C; Furrer, H; Muga, R; Porter, K; Girardi, E(2013). Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax, 68(3), 207 -213.
Touloumi, G; Pantazis, N; Pillay, D;Paraskevis, D; Chaix, ML; Bucher, HC; Kucherer, C; Zangerle, R; Kran, AM;Porter, K (2013). Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. Clinical Infectious Diseases, 56(6), 888 -897.
van der Helm, J; Geskus, R; Sabin, C; Meyer,L; Del Amo, J; Chene, G; Dorrucci, M; Muga, R; Porter, K; Prins, M (2013). Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after. Gastroenterology,144(4), 751 – 760.
2012
Huang, X.; Lodi, S.; Fox, Z.; Li, W.; Phillips,A.; Porter, K.; Lutsar, I.; Kelleher, A.; Li, N.; Xu, X.; Wu, H.; Johnson, AM.(2012). Rate of CD4 decline and HIV-RNA change following HIV Seroconversion inmen who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. Jaids-Journal of Acquired Immune Deficiency Syndromes
Jarrin, I; Pantazis, N; Gill, MJ; Geskus, R;Perez-Hoyos, S; Meyer, L; Prins, M; Touloumi, G; Johnson, A; Hamouda, O; deOlalla, PG; Porter, K; del Amo, J (2012). Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clinical Infectious Diseases, 54(1), 111 – 118.
2011
Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki,T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2011).EmergingTransmitted Drug Resistance in Treatment Naive Human Immunodeficiency Virus – 1CRF06_cpx Infected Patients in Estonia. Scandinavian Journal of Infectious Diseases, 43(2), 122 – 128.
Jaffe, HW; De Stavola, BL; Carpenter, LM;Porter, K; Cox, DR (2011). Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS, 25(11), 1395 – 1403.
Laisaar, K.-T.; Avi, R.; Dehovitz, J.;Uusküla, A. (2011). Estonia at the Threshold of the Fourth Decade of the AIDS Era inEurope. Aids Research and HumanRetroviruses, 27(8), 841 – 851.
Lutsar, Irja (2011). Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Archives of Internal Medicine, 171(17), 1560 – 1569.
Mussini, C; Cossarizza, A; Sabin, C; Babiker, A; De Luca, A; Bucher, HC; Fisher, M; Rezza, G; Porter, K; Dorrucci, M (2011). Decline of CD4(+) T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. AIDS, 25(8), 1041 – 1049.
van der Helm, JJ; Prins, M; del Amo, J;Bucher, HC; Chene, G; Dorrucci, M; Gill, J; Hamouda, O; Sannes, M; Porter, K;Geskus, RB (2011). The hepatitis C epidemic among HIV-positive MSM: incidence estimatesfrom 1990 to 2007. AIDS, 25(8),1083 – 1091.
2010
Huik, K.; Sadam, M.; Karki, T.; Avi, R.;Krispin, T.; Paap, P.; Rüütel, K.; Uusküla, A.; Talu, A.; Abel-Ollo, K.;Lutsar, I. (2010). CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. The Journal of Infectious Diseases, 730 -739.
Avi, R.; Huik, K.; Sadam, M.; Karki, T.;Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I.(2010). Characterization of Integrase Region Polymorphisms in HIV-1 CRF06_cpxViruses in Treatment Naïve Patients in Estonia. Aids Research and Human Retroviruses, 26(10), 1109 – 1113.
2009
Avi, R; Huik, K; Sadam, M; Karki, T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2009). Absence of Genotypic Drug Resistance and Presence of Several Naturally Occurring Polymorphisms of Human Immunodeficiency Virus-1 CRF06_cpx in Treatment-Naive Patients in Estonia. Journal of Medical Virology, 81(6), 953 – 958.
2008
Bhaskarran, K.; Hamouda, O.; Sannes, M.;Bonfassa, F.; Johnson, A.M.; Lambert, P.C.; Porter, K.; CASCADE, Collaboration(2008). Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population. JAMA: the journal of the American Medical Association, 300(1), 51 – 59.
Jarrin, I.; Geskus, R.; Bhaskaran, K.; Prins, M.; Perez-Hoyos, S.; Muga, R.; Hernández-Aguado, I.; Meyer, L.; Porter, K.; del Amo, J.; Group author CASCADE Collaboration, (incl. I.Lutsar). (2008). Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. American Journal of Epidemiology, 168(5), 532 – 540.
Touloumi, G.; Pantazis, N.; Stirnadel, HA.;Walker, AS.; Boufassa, F.; Vanhems, P.; Porter, K. (2008). Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice. Jaids-Journal of Acquired Immune Deficiency Syndromes, 49(5), 492 – 498.
2005
Lutsar, I. (2005). HI-viirusinfektsioon kui globaalne probleem. Eesti Arst,4, 238 – 243.
